Effect of Intravenous Immunoglobulin as Adjuvant Therapy for Septic Shock Patients Admitted to Alexandria University Pediatric Intensive Care Unit

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202411838959146

Enrollment

Registered

2024-11-14

Start date

2024-05-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatrics

Interventions

Immunoglobulin group

Standard Group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Septic shock

Exclusion criteria

Exclusion criteria: Primary immunodeficiency Secondary immunodeficiency Reaction or hypersensitivity to IVIG Protein losing enteropathy, nephrotic syndrome or lymphangiectasia. The following medication: Steroids (oral or parenteral daily dose of = 0.15 mg/kg/day of prednisone or equivalent), for a duration of 30 days or more. Other immunosuppressive drugs or chemotherapy Guillain–Barré syndrome Myasthenia gravis Inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis) Idiopathic (autoimmune) thrombocytopenic purpura (ITP) .

Design outcomes

Primary

Measure	Time frame
Death	—

Secondary

Measure	Time frame
Length of PICO stay (LOS)	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026